Skip to main content
Clinical Trials/NCT04933461
NCT04933461CompletedNot Applicable

Simulated Clinical Use Testing to Evaluate Sharps Injury Prevention Features of HTL-STREFA's Safety Lancets (Test C)

HTL-Strefa S.A.4 sites in 1 country20 target enrollmentStarted: September 24, 2019Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
20
Locations
4
Primary Endpoint
The true failure rate of the tested devices.

Study Overview

Brief Summary

A simulated clinical use testing to evaluate the Medlance Plus and myLance sharps injury prevention feature in accordance with the FDA's guidance on medical devices with sharps injury prevention features.

Detailed Description

This study aims to evaluate the safety of the use of the following safety lancets: Medlance Plus and myLance in the prevention of needle-stick injury (NSI) and to evaluate the user's opinion with regard to the handling characteristics of the medical devices.

The simulated use clinical study involves healthcare professionals (HCPs) who routinely use safety lancets to collect blood samples.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • evaluators who routinely use safety lancets to collect capillary blood samples (prevention of the learning curve artifacts)
  • evaluators will be United States (US) residents
  • evaluators can read, write, and speak English
  • evaluators are at least 18 years old
  • evaluators are able to understand and provide signed consent for the study
  • evaluators are willing to comply with the study protocol, including being willing to answer questions and complete questionnaires.
  • evaluators have no concerns about the ability to perform the simulated skin pricking.

Exclusion Criteria

  • evaluators who do not routinely use safety lancets to collect capillary blood samples,
  • evaluators who cannot read, write, and speak English,
  • evaluators or a family member have a business or consulting relationship with a pharmaceutical or medical device company, or
  • evaluators who have participated in a product evaluation or marketing study involving safety lancets within the last six months

Outcomes

Primary Outcomes

The true failure rate of the tested devices.

Time Frame: At time of testing, up to 90 minutes

Effectiveness of the safety lancet's sharps injury prevention features.

Time Frame: At time of testing, up to 90 minutes

Evaluator questionnaire using five-point response Likert scale (coded from 1 "strongly disagree" to 5 "strongly agree") to measure respondents' attitudes to a particular question or statement. Numbers assigned to Likert scale express a "greater than" relationship.

Secondary Outcomes

  • Evaluation of various aspects of the ease of use.(At time of testing, up to 90 minutes ])
  • Evaluation of the safety of the devices based on the evaluators' assessments.(At time of testing, up to 90 minutes ])
  • Detection of any handling, usability questions / issues associated with the device.(At time of testing, up to 90 minutes ])

Investigators

Sponsor
HTL-Strefa S.A.
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (4)

Loading locations...

Similar Trials

Simulated Clinical Use Testing to Evaluate... | Clinical Trial